-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, "700,000 injections of sky-high medicine into medical insurance" appeared on the hot search
.
It is talking about the high-priced drug Nosinagen Sodium Injection for the treatment of Spinal Muscular Atrophy (SMA), which has been "bargained by the soul" of the National Medical Insurance Bureau, and the price has been reduced from 700,000 yuan per injection to 33,000 yuan per injection.
This can be said to be a New Year's gift for SMA patients and their families
.
Some people calculated the account.
The executive meeting of the State Council held on January 10 made it clear that the centralized procurement of drugs and high-value medical consumables should be carried out in a normalized and institutionalized manner
.
This move, through the market-oriented mechanism, squeezed the artificially high drug prices and guided the prices back to a reasonable level, which is undoubtedly good news for patients
The issue of inflated prices of medicines was brought to the National Standing Committee, which shows that the country attaches great importance to the problems in the field of medicine circulation
.
Since its launch in 2018, it has organized and carried out several centralized drug purchases
The medical purchasing power originally held by medical institutions was centralized to the medical insurance department for unified purchasing, and more than half of the "water" was squeezed out in one concentration
.
This shows that the field of pharmaceutical circulation really needs to be improved, and the transparency of the purchase and sale links needs to be enhanced
It is true that the special listing mechanism of drugs makes many special drugs expensive
.
However, in the previous recruitment and procurement system, the price of drugs was inflated.
From a policy perspective, the state has taken action to control related phenomena in the pharmaceutical field, and has put forward a series of linkage measures for the links such as bidding, procurement, promotion, and prescription, targeting corruption in the field of pharmaceutical purchase and sales, and clarified specific norms
.
Among them, the implementation of the reform of centralized drug procurement with volume can be said to further promote fair competition among pharmaceutical companies and squeeze the cost of intermediate links
The common people's medicine should be the common people's price, reasonable price
.
According to the relevant deployment, the national centralized procurement work will be upgraded in 2022, not only the collection quantity will increase, but also the collection varieties will be expanded
